Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arrowhead Pharma
(NQ:
ARWR
)
23.83
-0.25 (-1.04%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Arrowhead Pharma
< Previous
1
2
3
4
5
Next >
Arrowhead Pharmaceuticals to Participate in Upcoming June 2022 Conferences
June 07, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics
May 26, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results
May 10, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Breaks Ground on New Manufacturing Facility with Wisconsin Governor Tony Evers and Announces Receipt of Incentives
May 09, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors
May 02, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming May 2022 Conferences
May 02, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Host Pulmonary R&D Day
April 27, 2022
From
Arrowhead Pharmaceuticals Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia
April 26, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at Greater China Market
April 25, 2022
From
Arrowhead Pharmaceuticals Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Second Quarter Results
April 20, 2022
From
Arrowhead Pharmaceuticals Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
April 06, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences
April 01, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases
March 24, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
March 15, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia
February 24, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Arrowhead Pharmaceuticals, Inc. (ARWR) Investigation
February 21, 2022
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Arrowhead Pharmaceuticals, Inc. (ARWR) Investigation
February 18, 2022
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
February 18, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022
February 17, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results
February 02, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Announces Closing of Agreement with GlaxoSmithKline
January 24, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 First Quarter Results
January 21, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
January 12, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities
December 20, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 17, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming December 2021 Conferences
November 30, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results
November 22, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD
November 22, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Announces JNJ-75220795 in Development for NASH
November 17, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection
November 15, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.